The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1–40).
Open accessAbstract
We reported earlier that the levels of Ca 2+ -dependent metalloproteinases are increased in Alzheimer’s disease (AD) specimens, relative to control specimens. Here we show that these enzymes are forms of the matrix metalloproteinase MMP-9 (EC 3.4.24.35 ) and are expressed in the human hippocampus. Affinity-purified antibodies to MMP-9 labeled pyramidal neurons, but not granular neurons or glial cells. MMP-9 mRNA is expressed in pyramidal neurons, as determined with digoxigenin-labeled MMP-9 riboprobes, and the presence of this mRNA is confirmed with reverse transcriptase PCR. The cellular distribution of MMP-9 is altered in AD because 76% of the total 100 kDa enzyme activity is found in the soluble fraction of control specimens, whereas only 51% is detectable in the same fraction from AD specimens. The accumulated 100 kDa enzyme from AD brain is latent and can be converted to an active form with aminophenylmercuric acetate. MMP-9 also is detected in close proximity to extracellular amyloid plaques. Because a major constituent of plaques is the 4 kDa β-amyloid peptide, synthetic Aβ 1–40 was incubated with activated MMP-9. The enzyme cleaves the peptide at several sites, predominantly at Leu 34 -Met 35 within the membrane-spanning domain. These results establish that neurons have the capacity to synthesize MMP-9, which, on activation, may degrade extracellular substrates such as β-amyloid. Because the latent form of MMP-9 accumulates in AD brain, it is hypothesized that the lack of enzyme activation contributes to the accumulation of insoluble β-amyloid peptides in plaques.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increasing in vitro evidence indicates that some MMPs may play an important role in degrading soluble Ab (sAb), such as secreted MMP-2 and MMP-9 that generate C-terminally truncated Ab fragments and membrane-type MMP-14 that degrades both soluble and fibrillary Ab (29)(30)(31)(32).”
From Differential protective effects of connective tissue growth factor against Aβ neurotoxicity on neurons and glia (2017) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MMP-9 is capable of cleaving Aβ in vitro (Backstrom et al., 1996)”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Backstrom et al., 1996
In the citing paper
“In parallel, a number of these CNS diseases exhibit dysregulated expression of enzymes necessary for PNN cleavage and reorganization (Backstrom et al., 1996; Lorenzl et al., 2003; Rybakowski et al., 2009; Kim et al., 2009; Zhang et al., 2011; Yamamori et al., 2013; Liu et al., 2014; Rankin-Gee et al., 2015; Lepeta et al., 2017).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Backstrom et al., 1996
In the citing paper
“plasma levels of MMP-9 are elevated in AD patients (Backstrom et al., 1996; Lorenzl et al., 2003).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Backstrom et al., 1996
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,515
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · cited 1×
“The diagnosis of AD was confirmed by postmortem neuropathological examination via the diagnostic criteria of the Consortium to Establish a Registry for Alzheimer’s Disease, a modification of the Khachaturian protocol (Khachaturian, 1985).”
MethodHeussen, C., & Dowdle, E. B. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90338-3 · Cited by 1,989
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Cleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,403
Wilhelm, S. M., Collier, I. E., Marmer, B. L., Eisen, A. Z., Grant, G. A., & Goldberg, G. I. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71480-4 · Cited by 1,109
Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa‐Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,093
Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity
Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S., & Ito, H. (1988) · Nature · doi:10.1038/331530a0 · Cited by 1,083
A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors
Ponte, P. A., Gonzalez‐DeWhitt, P. A., Schilling, J., Miller, J., Hsu, D. K., Greenberg, B., Davis, K. L., Wallace, W., Lieberburg, I. M., Fuller, F. H., et al. (1988) · Nature · doi:10.1038/331525a0 · Cited by 1,050
Abraham, C. R., Selkoe, D. J., & Potter, H. (1988) · Cell · doi:10.1016/0092-8674(88)90462-x · Cited by 900
Evidence that β-Amyloid Protein in Alzheimer's Disease Is Not Derived by Normal Processing
Sisodia, S. S., Koo, E. H., Beyreuther, K. T., Unterbeck, A., & Price, D. L. (1990) · Science · doi:10.1126/science.1691865 · Cited by 894
Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein
Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 834
Springman, E. B., Angleton, E. L., Birkedal‐Hansen, H., & Wart, H. E. V. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.1.364 · Cited by 713
Ogata, Y., Enghild, J. J., & Nagase, H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50563-4 · Cited by 629
Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase.
Hibbs, M. S., Hasty, K. A., Seyer, J. M., Kang, A. H., & Mainardi, C. L. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89580-1 · Cited by 613
Inverse association of anti‐inflammatory treatments and Alzheimer's disease
Breitner, J. C. S., Gau, B. A., Welsh-Bohmer, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 569
Goldberg, G. I., Strongin, A. Y., Collier, I. E., Genrich, L., & Marmer, B. L. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42873-6 · Cited by 513
Okada, Y., Gonoji, Y., Naka, K., Tomita, K., Nakanishi, I., Iwata, K., Yamashita, K., & Hayakawa, T. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36670-0 · Cited by 501
Oltersdorf, T., Fritz, L. C., Schenk, D. B., Lieberburg, I. M., Johnson‐Wood, K., Beattie, E. C., Ward, P. J., Blacher, R. W., Dovey, H. F., & Sinha, S. (1989) · Nature · doi:10.1038/341144a0 · Cited by 457
Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid β-protein precursor
Nostrand, W. E. V., Wagner, S. L., Suzuki, M., Choi, B. H., Farrow, J. S., Geddes, J. W., Cotman, C. W., & Cunningham, D. D. (1989) · Nature · doi:10.1038/341546a0 · Cited by 434
Matsas, R., Fulcher, I. S., Kenny, A. J., & Turner, A. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.10.3111 · Cited by 372
Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro.
Simmons, L. K., May, P. C., Tomaselli, K. J., Rydel, R. E., Fuson, K. S., Brigham, E. F., Wright, S., Lieberburg, I. M., Becker, G. W., & Brems, D. N. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10007-2 · Cited by 371
Inflammatory mechanisms in Alzheimer's disease: implications for therapy
Aisen, P. S. S., & Davis, K. L. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1105 · Cited by 326
Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils.
Peppin, G. J., & Weiss, S. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4322 · Cited by 258
MORODOMI, T., Ogata, Y., Sasaguri, Y., Morimatsu, M., & Nagase, H. (1992) · Biochemical Journal · doi:10.1042/bj2850603 · Cited by 190
A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor
Miyazaki, K., Hasegawa, M. L., Funahashi, K., & Umeda, M. (1993) · Nature · doi:10.1038/362839a0 · Cited by 175
Netzel–Arnett, S., Sang, Q. A., Moore, W. G. I., Navre, M., Birkedal‐Hansen, H., & Wart, H. E. V. (1993) · Biochemistry · doi:10.1021/bi00076a016 · Cited by 173
The latent collagenase and gelatinase of human polymorphonuclear neutrophil leucocytes
Murphy, G., Bretz, U., Baggiolini, M., & Reynolds, J. J. (1980) · Biochemical Journal · doi:10.1042/bj1920517 · Cited by 165
Moll, U. M., Youngleib, G. L., Rosinski, K. B., & Quigley, J. P. (1990) · PubMed · Cited by 149
Shah, S. V., Baricos, W. H., & Başçı, A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112790 · Cited by 143
Proteolysis of Aβ Peptide from Alzheimer Disease Brain by Gelatinase A
Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J., & Fridman, R. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2872 · Cited by 135
Matrix Metalloproteinases in the Neocortex and Spinal Cord of Amyotrophic Lateral Sclerosis Patients
Lim, G. P., Backstrom, J. R., Cullen, M. J., Miller, C. A., Atkinson, R., & Tökés, Z. A. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67010251.x · Cited by 125
Self-citationBackstrom, J. R., Miller, C. A., & Tökés, Z. A. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09352.x · Cited by 109
Self-citationFulcher, I. S., & Kenny, A. J. (1983) · Biochemical Journal · doi:10.1042/bj2110743 · Cited by 101
Matrix degrading metalloproteinases
Ennis, B. W., & Matrisian, L. M. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01050416 · Cited by 99
Davies, D. C., Horwood, N., Isaacs, S. L., & Mann, D. M. A. (1992) · Acta Neuropathologica · doi:10.1007/bf00310028 · Cited by 88
Devarajan, P., Johnston, J. J., Ginsberg, S. S., Wart, H. E. V., & Berliner, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74029-0 · Cited by 80
The 84‐kDa Form of Human Matrix Metalloproteinase‐9 Degrades Substance P and Gelatin
Backstrom, J. R., & Tökés, Z. A. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64031312.x · Cited by 64
Self-citationActivation of human neutrophil gelatinase by endogenous serine proteinases
Vissers, M. C. M., & Winterbourn, C. C. (1988) · Biochemical Journal · doi:10.1042/bj2490327 · Cited by 51
Papastoitsis, G., Siman, R., Scott, R. W., & Abraham, C. R. (1994) · Biochemistry · doi:10.1021/bi00167a025 · Cited by 49
Yamada, T., Miyazaki, K., Koshikawa, N., Takahashi, M., Akatsu, H., & Yamamoto, T. (1995) · Acta Neuropathologica · doi:10.1007/bf00309334 · Cited by 45
MCDERMOTT, J. R., & GIBSON, A. M. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91691-5 · Cited by 31
Quantitative Measurement of Relative Gene Expression in Human Tumors
Horikoshi, T., Danenberg, K. D., Volkenandt, M., Stadlbauer, T. H. W., & Danenberg, P. V. (2003) · Humana Press eBooks · doi:10.1385/0-89603-244-2:177 · Cited by 23
Schönlein, C., Löffler, J., & Huber, G. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1667 · Cited by 20
Research works printed but not linked: 3
- 10.1016/0003-2697(87)90021-2 · DOI
- Davis, 1990, A latent M r 94,000 gelatin-degrading metalloproteinase induced during differentiation of HL-60 promyelocytic leukemia cells: a member of the collagenase family of enzymes., Cancer Res, 50, 1113
- Potter H Abraham CR Dressler D (1991) The Alzheimer amyloid components α1-antichymotrypsin and β-protein form a stable complex in vitro. in Alzheimer’s disease: basic mechanisms, diagnosis, and therapeutic strategies, eds Iqbal K McLachlan DRC Winblad B Wisniewski HM (Wiley, New York), pp 275–279.
Cited by
Sorted by citations
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances
Huang, H. (2018) · Sensors · doi:10.3390/s18103249 · Cited by 769
“In extracellular space, some polypeptides can also be cleaved by MMP-9 [39].”
BackgroundMatrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579
“…2006;Wang et al., 2012), aminopeptidase (Sevalle et al., 2009; Dhanavade and Sonawane, 2014), gelatinase A (Yamada et al., 1995b; Jalkute et al., 2015), matrix metalloendopeptidase-9 (Backstrom et al., 1996), coagulation factor Xia (Saporito-Irwin and Van Nostrand, 1995), antibody light chain c23.”
Metadata
- Authors
- Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A.
- Affiliations
- University of Southern California (US)
- ORCID
- Cullen, Michael J.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 1996-12-15
- Volume
- 16
- Issue
- 24
- Pages
- 7910-7919
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W4296941341
- Cited by
- 331
- References
- 46
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 21 · 2019: 5 · 2018: 13 · 2017: 15 · 2016: 11 · 2015: 18 · 2014: 18 · 2013: 8 · 2012: 12
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Funders
- National Institute on Aging (R01-AG09681)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- MMP-9, Alzheimer's disease, Aβ40, hippocampal pyramidal neurons, MMP-9 mRNA expression, extracellular matrix metalloproteinases, transmembrane domain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
